Skip to Content

'
Stephen F. Kry, Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Member, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX

Education & Training

Degree-Granting Education

2007 The University of Texas MD Anderson Cancer Center, Houston, TX, PHD, Medical Physics
2003 The University of Texas MD Anderson Cancer Center, Houston, TX, MS, Medical Physics
1999 University of British Columbia, Vancouver, Canada, B.Sc., Honors Physics

Experience/Service

Academic Appointments

Graduate Research Assistant, Department of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000-2007
Teaching Assistant, University of British Columbia, Vancouver, Canada, 1999

Selected Publications

Peer-Reviewed Original Research Articles
1. Serago C, Burmeister JW, Dunscombe PB, Gale A, Hendee WR, Kry SF. Recommended ethics curriculum for medical physics graduate and residency programs. Report of Task Group 159. Med Phys. In Press.
2. Kry SF, Vassiliev ON, Mohan R. Out-of-field photon dose following removal of the flattening filter from a medical accelerator. Phys Med Biol 55(8):2155-2166, 4/21/2010. e-Pub 3/19/2010. PMID: 20305334.
3. Wang Z, Howell RM, Burgett EA, Kry SF, Hertel NE, Salehpour M. Calibration of indium response functions in an Au-In-BSE system up to 800 MeV. Radiat Prot Dosimetry 139(4):565-573, 2010. e-Pub 12/15/2009. PMID: 20008907.
4. Price MJ, Kry SF, Eifel PJ, Salehpour M, Mourtada F. Dose perturbation due to the polysulfone cap surrounding a Fletcher-Williamson colpostat. J Appl Clin Med Phys 11(1):3146, 2010. PMID: 20160700.
5. Howell RM, Kry SF, Burgett E, Followill D, Hertel NE. Effects of tertiary MLC configuration on secondary neutron spectra from 18-MV x-ray beams for the Varian 21 EX linear accelerator. Med Phys 36(9):4039-4046, 9/2009. PMCID: PMC2738743.
6. Howell RM, Kry SF, Burgett E, Hertel NE, Followill DS. Secondary neutron spectra from modern Varian, Siemens, and Elekta linacs with multileaf collimators. Med Phys 36(9):4027-4038, 9/2009. PMCID: PMC2738742.
7. Kry SF, Salehpour M, Titt U, White RA, Stovall M, Followill D. Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy. Radiother Oncol 91(1):132-7, 4/2009. e-Pub 1/13/2009. PMID: 19147246.
8. Kry SF, Howell RM, Salehpour M, Followill DS. Neutron spectra and dose equivalents calculated in tissue for high-energy radiation therapy. Med Phys 36(4):1244-1250, 4/2009. PMCID: PMC2736753.
9. Kry SF, Howell RM, Polf J, Mohan R, Vassiliev ON. Treatment vault shielding for a flattening filter free medical linear accelerator. Phys Med Biol 54(5):1265-1273, 3/7/2009. e-Pub 2/3/2009. PMID: 19190359.
10. Wang Z, Howell RM, Kry SF, Burgett EA, Hertel NE, Salehpour MN. Characterization of a gold-and-indium dual-activation-foil-based bonner sphere system. Nuclear Technology 168:603-609, 2009.
11. Wang Z, Kry SF, Howell RM, Salehpour M. Comparison of unfolding methods for determining neutron spectrum and ambient dose equivalent. Nuclear Technology 168:610-614, 2009.
12. Kry SF, Price M, Wang Z, Mourtada F, Salehpour M. Investigation into the Use of a MOSFET Dosimeter as an Implantable Fiducial Marker. J Appl Clin Med Phys 10(1):22-32, 2009. PMID: 19223838.
13. Howell RM, Burgett E, Hertel NE, Kry SF, Wang Z, Salehpour M. Measurement of high-energy neutron spectra with Bonner Extension (BSE) system. Nuclear Technology 168:333-339, 2009.
14. Vassiliev ON, Kry SF, Chang JY, Balter PA, Titt U, Mohan R. Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac. J Appl Clin Med Phys 10(1):2880, 2009. PMID: 19223837.
15. Kry SF, Howell RM, Titt U, Salehpour M, Mohan R, Vassiliev ON. Energy Spectra, Sources, and Shielding Considerations for Neutrons Generated by a Flattening Filter-Free Clinac. Med Phys 35(5):1906-1911, 5/2008. PMID: 18561666.
16. Kry SF, Titt U, Followill D, Pönisch F, Vassiliev ON, White RA, Stovall M, Salehpour M. A Monte Carlo model for out-of-field dose calculation from high-energy photon therapy. Med Phys 34(9):3489-99, 9/2007. PMID: 17926952.
17. Vassiliev ON, Kry SF, Kuban DA, Salehpour M, Mohan R, Titt U. Treatment-planning study of prostate cancer intensity-modulated radiotherapy with a Varian Clinac operated without a flattening filter. Int J Radiat Oncol Biol Phys 68(5):1567-71, 8/2007. e-Pub 6/2007. PMID: 17544596.
18. Kry SF, Followill D, White RA, Stovall M, Kuban DA, Salehpour M. Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. Int J Radiat Oncol Biol Phys 68(4):1265-71, 7/2007. PMID: 17637398.
19. Kry SF, Starkschall G, Antolak JA, Salehpour M. Evaluation of the Accuracy of Fetal Dose Estimates Using TG-36 Data. Med Phys 34(4):1193-1197, 2007. PMID: 17500450.
20. Vassiliev ON, Titt U, Kry SF, Mohan R, Gillin MT. Radiation safety survey on a flattening filter-free medical accelerator. Radiat Prot Dosimetry 124(2):187-90, 2007. e-Pub 8/6/2007. PMID: 17681966.
21. Kry SF, Titt U, Poenisch F, Vassiliev ON, Salehpour M, Gillin M, Mohan R. Reduced Neutron Production Through Use of a Flattening Filter Free Accelerator. Int J Radiat Oncol Biol Phys 68(4):1260-1264, 2007. PMID: 17637397.
22. Kry SF, Price MJ, Followill D, Mourtada F, Salehpour M. The Use of LiF (TLD-100) as an Out-of Field Dosimeter. J Appl Clin Med Phys 8(4):169-175, 2007. PMID: 18449155.
23. Kry SF, Titt U, Poenisch F, Followill D, Vassiliev ON, White RA, Mohan R, Salehpour M. A Monte Carlo Model for Calculating Out-of-Field Dose from a Varian 6-MV Beam. Med Phys 33(11):4405-4413, 2006. PMID: 17153419.
24. Vassiliev ON, Titt U, Poenisch F, Kry SF, Mohan R, Gillin MT. Dosimetric Properties of Photon Beams From a Flattening Filter Free Clinical Accelerator. Phys Med Biol 51(7):1907-1917, 2006. e-Pub 3/2006. PMID: 16552113.
25. Ponisch F, Titt U, Kry SF, Vassiliev ON. MCNPX Simulation of a Multileaf Collimator. Med Phys 33(2):402-404, 2006. PMID: 16532947.
26. Titt U, Vassiliev ON, Ponisch F, Kry SF, Mohan R. Monte Carlo Study of Backscatter in a Flattening Filter Free Clinical Accelerator. Med Phys 33(9):3270-3273, 2006. PMID: 17022221.
27. Vassiliev ON, Titt U, Kry SF, Ponisch F, Gillin MT, Mohan R. Monte Carlo Study of Photon Fields from a Flattening Filter Free Clinical Accelerator. Med Phys 33(4):820-827, 2006. PMID: 16696457.
28. Ponisch F, Titt U, Vassiliev ON, Kry SF, Mohan R. Properties of Unflattened Photon Beams Shaped by a Multi Leaf Collimator. Med Phys 33(6):1738-1746, 2006. PMID: 16872081.
29. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, Rosen II. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62(4):1195-203, 7/2005. PMID: 15990025.
30. Kry SF, Salehpour M, Followill D, Stovall M, Kuban D, White RA, Rose I. Out of Field Photon and Neutron Dose Equivalents from Step and Shoot Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 62(4)(4):1204-1216, 2005. PMID: 15990026.
31. Followill D, Stovall M, Kry SF, Ibbott G. Neutron Source Strength Measurements for Varian, Siemens, Elekta, and General Electric Linear Accelerators. J Appl Clin Med Phys 4(3):189-194, 2003. PMID: 12841788.
32. Suprunowicz R, Butler RM, Ford COK, Kry SF. An Experimental Investigation of Conbergent Flow to Horizontal Wells. Jour of Canadian Petroleum Technology 37(10):51-57, 1998.

Grant & Contract Support

Title: Dose calculation tools for epidemiology studies following modern radiotherapy
Funding Source: National Cancer Institute-DHHS-NIH
Role: Principal Investigator
Duration: 4/1/2011 - 3/31/2013
 
Title: A calculation method for patient specific dosimetry for epidemiological studies of radiation induced second cancers
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Howell
Duration: 12/1/2009 - 11/30/2011
 
Title: Phantom Measurements and Validation of High-Dose DVS
Funding Source: Sicel
Role: Principal Investigator
Duration: 12/1/2007 - 1/31/2008

Last updated: 10/13/2010